Black Titan (NASDAQ:BTTC – Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.10) EPS for the quarter, FiscalAI reports.
Black Titan Stock Down 0.3%
BTTC opened at $0.28 on Friday. The business has a 50 day moving average price of $0.43 and a 200 day moving average price of $0.97. Black Titan has a twelve month low of $0.28 and a twelve month high of $10.05. The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.62 and a current ratio of 4.62. The firm has a market cap of $3.02 million, a P/E ratio of -0.10 and a beta of 1.21.
About Black Titan
Titan Pharmaceuticals, Inc is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.
Featured Stories
- Five stocks we like better than Black Titan
- The Ugly Truth Behind SoundHound’s Q3 Results
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
Receive News & Ratings for Black Titan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Titan and related companies with MarketBeat.com's FREE daily email newsletter.
